Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: Quantitative analysis of ADC and SUV

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 842-852

  Varoquaux, Arthur ^a   Rager, Olivier ^a   Lovblad, Karl Olof ^a   Masterson, Karen ^a   Dulguerov, Pavel ^a   Ratib, Osman ^a   Becker, Christoph D ^a   Becker, Minerva ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Carcinoma; Diffusion weighted magnetic resonance imaging; Molecular imaging; Neoplasms; Positron emission tomography and computed tomography; Squamous cell of head and neck

Indexed keywords

AMALGAM; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFACT; BREATHING; CELL DEDIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; MALE; MATHEMATICAL PARAMETERS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PHYSICAL PARAMETERS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; SWALLOWING; YOUNG ADULT; CELL DIFFERENTIATION; HEAD AND NECK TUMOR; IMAGE PROCESSING; METABOLISM; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; OBSERVER VARIATION; RECURRENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891692378     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2351-9     Document Type: Article

References (48)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
2. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol 2009;2009:208725.
3. 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology 2009;51:677-86.
4. Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18] fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J Otorhinolaryngol Relat Spec 2001;63:307-13.
5. Keen H, Pichler B, Kukuk D, Duchamp O, Raguin O, Shannon A, et al. An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3′- deoxy-3′-[18F] -fluorothymidine uptake in human tumor xenograft models. Mol Imaging Biol 2012;14:355-65.
6. Chen Z, Ma L, Lou X, Zhou Z. Diagnostic value of minimum apparent diffusion coefficient values in prediction of neuroepithelial tumor grading. J Magn Reson Imaging 2010;31:1331-8.
7. Zhang X-Y, Sun Y-S, Tang L, XueW-C, Zhang X-P. Correlation of diffusion-weighted imaging data with apoptotic and proliferation indexes in CT26 colorectal tumor homografts in balb/c mouse. J Magn Reson Imaging 2011;33:1171-6.
8. Thoeny HC, De Keyzer F, King AD. Diffusion-weighted MR imaging in the head and neck. Radiology 2012;263:19-32.
9. Wong CS, Gong N, Chu Y-C, Anthony M-P, Chan Q, Lee HF, et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 2011;81:2122-6.
10. 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol 2012;81:2913-8.
11. Ho K-C, Lin G,Wang J-J, Lai C-H, Chang C-J, Yen T-C. Correlation of apparent diffusion coefficientsmeasured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 2009;36:200-8.
12. Wu X, Korkola P, Pertovaara H, Eskola H, Järvenpää R, Kellokumpu-Lehtinen P-L. No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study. Eur J Radiol 2011;79:e117-21.
13. Fruehwald-Pallamar J, Czerny C, Mayerhoefer ME, Halpern BS, Eder-Czembirek C, Brunner M, et al. Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. Eur J Nucl Med Mol Imaging 2011;38:1009-19.
14. 18F-FDG uptake with apparent diffusion coefficient ratio measured on standard and high b value diffusion MRI in head and neck cancer. J Nucl Med 2011;52:1056-62.
15. NakajoM, Nakajo M, KajiyaY, Tani A, Kamiyama T,Yonekura R, et al. FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Clin Nucl Med 2012;37:475-80.
16. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun 2012;33:305-12.
17. Verhappen MH, Pouwels PJW, Ljumanovic R, van der Putten L, Knol DL, De Bree R, et al. Diffusion-weighted MR imaging in head and neck cancer: comparison between half-Fourier acquired single-shot turbo spin-echo and EPI techniques. AJNR Am J Neuroradiol 2012;33:1239-46.
18. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000;27:643-6.
19. Donner A, Koval JJ. The estimation of intraclass correlation in the analysis of family data. Biometrics 1980;36:19-25.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
21. KruskalW,Wallis A.Use of ranks in one-criterion variance Analysis. J Am Stat Assoc 1952;47:583.
22. Kwee TC, Takahara T, Luijten PR, Nievelstein RAJ. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 2010;75:215-20.
23. Vandecaveye V, De Keyzer F, Vander Poorten V, Dirix P, Verbeken E, Nuyts S, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009;251:134-46.
24. Vandecaveye V, Dirix P, De Keyzer F, de Beeck KO, Vander Poorten V, Roebben I, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010;20:1703-14.
25. Choi S, Cunningham DT, Aguila F, Corrigan JD, Bogner J, Mysiw WJ, et al. DTI at 7 and 3 T: systematic comparison of SNR and its influence on quantitative metrics. Magn Reson Imaging 2011;29:739-51.
26. Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007;67:960-71.
27. Tshering Vogel DW, Zbaeren P, Geretschlaeger A, Vermathen P, De Keyzer F, Thoeny HC. Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers. Eur Radiol 2013;23:562-9.
28. Wang J, Takashima S, Takayama F, Kawakami S, Saito A, Matsushita T, et al. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 2001;220:621-30.
29. 18F-FDG-PET standardized uptake value, Tclassification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck? Eur Arch Otorhinolaryngol 2010;267:1635-40.
30. 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. AJR Am J Roentgenol 2011;197:976-80.
31. Chawla S, Kim S, Wang S, Poptani H. Diffusion-weighted imaging in head and neck cancers. Future Oncol 2009;5:959-75.
32. Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622-35.
33. Huisman TAGM, Loenneker T, Barta G, Bellemann ME, Hennig J, Fischer JE, et al.Quantitative diffusion tensorMRimaging of the brain: field strength related variance of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) scalars. Eur Radiol 2006;16:1651-8.
34. Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusionweighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011;33:128-35.
35. Notohamiprodjo M, Dietrich O, Horger W, Horng A, Helck AD, Herrmann KA, et al. Diffusion tensor imaging (DTI) of the kidney at 3 tesla-feasibility, protocol evaluation and comparison to 1.5 Tesla. Invest Radiol 2010;45:245-54.
36. Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009;15:986-94.
37. Fushimi Y, Miki Y, Okada T, Yamamoto A, Mori N, Hanakawa T, et al. Fractional anisotropy and mean diffusivity: comparison between 3.0-T and 1.5-T diffusion tensor imaging with parallel imaging using histogram and region of interest analysis. NMR Biomed 2007;20:743-8.
38. Matsuoka A, Minato M, Harada M, Kubo H, Bandou Y, Tangoku A, et al. Comparison of 3.0- and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med 2008;26:15-20.
39. Burger IA, Huser DM, Burger C, Von Schulthess GK, Buck A. Repeatability of FDG quantification in tumor imaging: averaged SUVs are superior to SUV(max). Nucl Med Biol 2012;39:666-70.
40. 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med 2009;50:1760-9.
41. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18FFDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008;49:1038-46.
42. Srinivasan A, Dvorak R, Rohrer S, Mukherji SK. Initial experience of 3-tesla apparent diffusion coefficient values in characterizing squamous cell carcinomas of the head and neck. Acta Radiol 2008;49:1079-84.
43. Ichikawa Y, Sumi M, Sasaki M, Sumi T, Nakamura T. Efficacy of diffusion-weighted imaging for the differentiation between lymphomas and carcinomas of the nasopharynx and oropharynx: correlations of apparent diffusion coefficients and histologic features. AJNR Am J Neuroradiol 2012;33:761-6.
44. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009;31:195-201.
45. Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012;82:548-53.
46. Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M,Wolden S, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-208.
47. Masterson K, Rager O, Kohler R, Wissmeyer M, Ratib O, Becker M. MR/PET image fusion: feasibility and utility in the locoregional assessment of head and neck cancer. SS415, Proceedings of the 11th Annual Congress Swiss Society of Nuclear Medicine, 3-5 June 2010, Lugano. Nuklearmed-Nucl Med 2010;49(3):A127.
48. Park SH, Moon WK, Cho N, Chang JM, Im S-A, Park IA, et al. Comparison of diffusion-weightedMRimaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2012;22:18-25.